INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
- Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
- Patients who received weekly XPro™ treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p
- Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer’s Disease.
- EEG's capability to assess brain function makes these findings particularly noteworthy for INmune Bio’s novel treatment strategy.